Year 2014,
Volume: 47 Issue: 3, 60 - 61, 01.12.2014
Abstract
Keywords
References
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in multicentre,
- controlled trial Lancet. 2012;380:358-65 3 randomised phase
- McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM- 3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323-32
- Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous
- vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities, Br J Dermatol 2012;167:987-94
- with 4. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Ann Oncol 2013;24:1691-7
- Lacouture ME, Duvic M, Hauschild A, et al. Analysis of Dermatologic Events in Vemurafenib-Treated Patients 2013;18:314-22 The Oncologist
Year 2014,
Volume: 47 Issue: 3, 60 - 61, 01.12.2014
Abstract
görülen cilt yan etkisi hastaların %64—75’inde görülen raş iken, makülopapüler raş %4—21 hastada bildirilmiştir (1—4). Vemurafenibe bağlı grad l—2 maküler raş gelişmesi durumunda ilacın aynı dozda devam edilmesi ve ek olarak topikal steroid, oral antihistaminik ve 0.5 mg/kg’dan oral steroid kullanılması, grad 3 toksisite durumundaysa ilacın kesilmesi ya da doz modifikasyonu önerilmektedir (5). Bununla birlikte hedefe yönelik tedavi kullanan hastalarda tedaviye ara verilmesinin ilaç direnci ile ilişkili olabileceği gözönüne alınarak bu hastaların cilt toksisitelerinin tıbbi onkoloji ve deneyimli dermatoloji klinikleri ile beraber multidisipliner takibi ve yönetimi
Keywords
References
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in multicentre,
- controlled trial Lancet. 2012;380:358-65 3 randomised phase
- McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM- 3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323-32
- Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous
- vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities, Br J Dermatol 2012;167:987-94
- with 4. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Ann Oncol 2013;24:1691-7
- Lacouture ME, Duvic M, Hauschild A, et al. Analysis of Dermatologic Events in Vemurafenib-Treated Patients 2013;18:314-22 The Oncologist
There are 7 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | December 1, 2014 |
| Published in Issue | Year 2014 Volume: 47 Issue: 3 |